X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with Biocon Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs BIOCON LTD - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

BIOCON LTD 
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS BIOCON LTD NOVARTIS/
BIOCON LTD
 
P/E (TTM) x 349.6 36.7 951.6% View Chart
P/BV x 17.2 4.9 352.5% View Chart
Dividend Yield % 1.7 1.5 110.7%  

Financials

 NOVARTIS   BIOCON LTD
EQUITY SHARE DATA
    NOVARTIS
Mar-16
BIOCON LTD
Mar-16
NOVARTIS/
BIOCON LTD
5-Yr Chart
Click to enlarge
High Rs982496 198.1%   
Low Rs556397 140.3%   
Sales per share (Unadj.) Rs252.9174.3 145.1%  
Earnings per share (Unadj.) Rs62.144.8 138.7%  
Cash flow per share (Unadj.) Rs63.356.9 111.2%  
Dividends per share (Unadj.) Rs10.005.00 200.0%  
Dividend yield (eoy) %1.31.1 116.0%  
Book value per share (Unadj.) Rs363.6202.8 179.3%  
Shares outstanding (eoy) m31.96200.00 16.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.02.6 118.8%   
Avg P/E ratio x12.410.0 124.3%  
P/CF ratio (eoy) x12.27.8 155.0%  
Price / Book Value ratio x2.12.2 96.1%  
Dividend payout %16.111.2 144.2%   
Avg Mkt Cap Rs m24,58089,220 27.6%   
No. of employees `0000.84.4 17.0%   
Total wages/salary Rs m1,8016,363 28.3%   
Avg. sales/employee Rs Th10,748.97,894.5 136.2%   
Avg. wages/employee Rs Th2,395.21,441.2 166.2%   
Avg. net profit/employee Rs Th2,641.12,029.7 130.1%   
INCOME DATA
Net Sales Rs m8,08334,854 23.2%  
Other income Rs m829845 98.2%   
Total revenues Rs m8,91335,699 25.0%   
Gross profit Rs m2348,200 2.9%  
Depreciation Rs m372,423 1.5%   
Interest Rs m2102 1.8%   
Profit before tax Rs m1,0256,520 15.7%   
Minority Interest Rs m0-744 0.0%   
Prior Period Items Rs m170-   
Extraordinary Inc (Exp) Rs m1,6965,754 29.5%   
Tax Rs m7522,569 29.3%   
Profit after tax Rs m1,9868,961 22.2%  
Gross profit margin %2.923.5 12.3%  
Effective tax rate %73.439.4 186.2%   
Net profit margin %24.625.7 95.6%  
BALANCE SHEET DATA
Current assets Rs m12,67839,932 31.7%   
Current liabilities Rs m2,43316,276 14.9%   
Net working cap to sales %126.767.9 186.7%  
Current ratio x5.22.5 212.4%  
Inventory Days Days3354 61.0%  
Debtors Days Days2286 26.1%  
Net fixed assets Rs m6939,101 0.2%   
Share capital Rs m1601,000 16.0%   
"Free" reserves Rs m11,46038,591 29.7%   
Net worth Rs m11,62140,556 28.7%   
Long term debt Rs m020,724 0.0%   
Total assets Rs m14,40084,816 17.0%  
Interest coverage x570.564.9 878.8%   
Debt to equity ratio x00.5 0.0%  
Sales to assets ratio x0.60.4 136.6%   
Return on assets %13.810.7 129.2%  
Return on equity %17.122.1 77.3%  
Return on capital %23.619.0 124.2%  
Exports to sales %0.730.7 2.4%   
Imports to sales %18.620.4 91.2%   
Exports (fob) Rs m6010,717 0.6%   
Imports (cif) Rs m1,5037,105 21.1%   
Fx inflow Rs m18611,789 1.6%   
Fx outflow Rs m1,8218,393 21.7%   
Net fx Rs m-1,6353,396 -48.1%   
CASH FLOW
From Operations Rs m2,5315,264 48.1%  
From Investments Rs m-8,270-9,540 86.7%  
From Financial Activity Rs m-38610,867 -3.5%  
Net Cashflow Rs m-6,1256,591 -92.9%  

Share Holding

Indian Promoters % 0.0 40.4 -  
Foreign collaborators % 75.0 20.6 364.1%  
Indian inst/Mut Fund % 2.0 8.4 23.8%  
FIIs % 1.6 10.7 15.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 19.9 108.0%  
Shareholders   41,647 109,995 37.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   DISHMAN PHARMA  GLENMARK PHARMA  AUROBINDO PHARMA  FRESENIUS KABI ONCO.  FDC LTD.  

Compare NOVARTIS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Strong Note; Bank & Realty Stocks Rally(Closing)

Indian share markets surged further in the afternoon session and finished in the green for the second straight session on heavy buying in realty stocks, metal stocks and bank stocks.

Related Views on News

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Biocon: High Other Income And Licensing Income Drive Growth (Quarterly Results Update - Detailed)

Nov 7, 2016

Biocon has announced its 2QFY17. The company has reported 19.8% YoY growth in net sales and profits of Rs 1.5 bn for the quarter. Here is our analysis of the results.

Biocon: Lower R&D Expenses Help Margin Expansion (Quarterly Results Update - Detailed)

Sep 19, 2016

Biocon has announced its 1QFY17. The company has reported 21.1% YoY growth in total income and 34.6% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

Aug 16, 2017

The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Aug 23, 2017 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS - WOCKHARDT LTD. COMPARISON

COMPARE NOVARTIS WITH

MARKET STATS